In-hospital safety and effectiveness of bivalirudin in percutaneous peripheral interventions: Data from a real-world registry

Journal of Endovascular Therapy

Volumn 17, Issue 1, 2010, Pages 31-36

  Shammas, Nicolas W ^a   Shammas, Gail A ^a   Jerin, Michael ^a   Dippel, Eric J ^a   Shammas, Andrew N ^a  

^a MIDWEST CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

Angioplasty; Anticoagulation; Bivalirudin; Complications; Hemorrhage; Heparin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; HEPARIN; HIRULOG; ANTICOAGULANT AGENT; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ADULT; AGED; AMPUTATION; ANGIOGRAPHY; ARTICLE; BLEEDING; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; ISCHEMIA; KIDNEY FAILURE; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS PERIPHERAL INTERVENTION; PRIORITY JOURNAL; STROKE; THROMBOEMBOLISM; THROMBUS; VASCULAR ACCESS; ANGIOPLASTY; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; HOSPITAL PATIENT; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; RADIOGRAPHY; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STATISTICS; STENOSIS, OCCLUSION AND OBSTRUCTION; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANGIOPLASTY; ANTICOAGULANTS; CHI-SQUARE DISTRIBUTION; CONSTRICTION, PATHOLOGIC; FEMALE; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; INPATIENTS; IOWA; ISCHEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PERIPHERAL VASCULAR DISEASES; RECOMBINANT PROTEINS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77952491631     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1583/09-2810.1     Document Type: Article

References (20)

1. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post infarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952-959. (Pubitemid 33131801)
2. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa during percutaneous coronary intervention; the REPLACE-2 randomized trial. JAMA. 2003;289:853-863.
3. Shah PB, Ahmed WH, Ganz P, et al. Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions. J Am Coll Cardiol. 1997;30:1264-1269.
4. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 2002;359:294-302.
5. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-2216.
6. Shammas NW, Lemke JH, Dippel EJ, et al. Inhospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. J Invasive Cardiol. 2003;15:242-246.
7. Shammas NW. Complications in peripheral vascular interventions: emerging role of direct thrombin inhibitors. J Vasc Interv Radiol. 2005;16(2 Pt 1):165-171. (Pubitemid 40322290)
8. Burgess JK, Chong BH. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol. 1997;58: 279-285.
9. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular- weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251-256. (Pubitemid 28067310)
10. Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin- induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003;15: 611-616.
11. Shammas NW. Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev. 2005 Winter;23(4):345-360.
12. Allie DE, Lirtzman MD, Wyatt CH, et al. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions. J Invasive Cardiol. 2003;15:334-342.
13. Shammas NW, Lemke JH, Dippel EJ, et al. Bivalirudin in peripheral vascular interventions: a single center experience. J Invasive Cardiol. 2003;15:401-404.
14. Allie DE, Hebert CJ, Lirtzman MD, et al. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome. J Invasive Cardiol. 2005;17:427-432.
15. Allie DE, Hall P, Shammas NW, et al. The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): in-hospital and 30-day results. J Invasive Cardiol. 2004; 16:651-656.
16. Katzen BT, Ardid MI, MacLean AA, et al. Bivalirudin as an anticoagulation agent: safety and efficacy in peripheral interventions. J Vasc Interv Radiol. 2005;16:1183-1187.
17. Marmur JD. Direct versus indirect thrombin inhibition in percutaneous coronary intervention. J Invasive Cardiol. 2002;14(Suppl B):8B-18B.
18. Ogilby JD, Kopelman HA, Klein LW, et al. Adequate heparinization during PTCA: assessment using activated clotting times. Cathet Cardiovasc Diagn. 1989;18:206-209.
19. Kleiman NS, Weitz JI. Putting heparin into perspective: its history and the evolution of its useduringpercutaneouscoronary interventions. J Invasive Cardiol. 2000;12(Suppl F):20F-26F.
20. Shammas NW, Allie D, Hall P, et al. Predictors of in-hospital and 30-day complications of peripheral vascular interventions using bivalirudin as the primary anticoagulant: results from the APPROVE Registry. J Invasive Cardiol. 2005;17:356-359.